Long-lasting, crystalline suspensions of injectable corticosteroids have been used to treat joint and soft-tissue disorders for many years; they decrease inflammation by reducing local infiltration of inflammatory cells and mediators. Depot formulations differ in their characteristics. Compounds with low solubility are thought to have the longest duration of action but may cause tissue atrophy when used in soft tissues. Intra-articular corticosteroids are commonly used to treat osteoarthritis and inflammatory arthritis: meta-analyses confirm their benefit in reducing pain and symptoms. Intra-articular corticosteroid injections have been shown to be safe and effective for repeated use (every 3 months) for up to 2 years, with no joint space narrowing detected. Fewer clinical trials are available for extra-articular uses for injectable corticosteroids, although there is evidence of efficacy in a variety of soft-tissue conditions. The accuracy of injections affects outcomes. Postinjection flare, facial flushing, and skin and fat atrophy are the most common side effects. Systemic complications of injectable corticosteroids are rare.





Polls results
1

On a scale of 1 to 10, rate how much this article will change your clinical practice?

NO change
BIG change
91% Article relates to my practice (11/12)
8% Article does not relate to my practice (1/12)
0% Undecided (0/12)
2

Will this article lead to more cost-effective healthcare?

50% Yes (6/12)
33% No (4/12)
16% Undecided (2/12)
3

Was this article biased? (commercial or personal)

0% Yes (0/12)
91% No (11/12)
8% Undecided (1/12)
4

What level of evidence do you think this article is?

0% Level 1 (0/12)
33% Level 2 (4/12)
25% Level 3 (3/12)
33% Level 4 (4/12)
8% Level 5 (1/12)